We found that knockdown of either APOL1 or ITGB4 increased sensitivity to gemcitabine in cells overexpressing ANGPTL4. This finding confirms that inhibition of APOL1 or ITGB4 can reverse resistance associated with ANGPTL4 expression in pancreatic cancer cells. The gene discussed is ITGB4; the disease is familial pancreatic carcinoma.